Sign in

    Difei Yang

    Managing Director and Senior Biotechnology Analyst at Mizuho Securities

    Dr. Difei Yang is a Managing Director and Senior Biotechnology Analyst at Mizuho Securities, specializing in gene therapy and SMID cap biotechnology equities. She covers emerging and established biotech companies, including Boundless Bio, and is recognized for picking high-performing stocks within the gene therapy space, consistently delivering impactful investment insights. Dr. Yang joined Mizuho in 2017 after holding senior analyst roles at Aegis Capital, Brean Capital, R.F. Lafferty, WallachBeth Capital, and Auriga Global Investors, alongside prior scientific and pharmaceutical industry leadership. Holding a Ph.D. in Chemistry from UCLA and an MBA from Georgia State University, she also maintains FINRA registration and securities licenses demonstrating her professional credentials.

    Difei Yang's questions to Boundless Bio (BOLD) leadership

    Difei Yang's questions to Boundless Bio (BOLD) leadership • Q2 2019

    Question

    Difei Yang of Mizuho Securities inquired about the typical timeframe to observe reduced ventilator utilization in AT132-treated patients and whether the higher dose might accelerate this onset of action.

    Answer

    Chairman and CEO Matt Patterson explained that respiratory function improves rapidly within weeks, leading to ventilator use reductions over the first 24 weeks. He noted that while the higher dose showed better results in tissue histopathology, a meaningful difference in the speed of clinical outcomes like ventilator reduction was not observed between the two doses.

    Ask Fintool Equity Research AI

    Difei Yang's questions to Boundless Bio (BOLD) leadership • Q4 2018

    Question

    Difei Yang of Mizuho Securities inquired about the extent of manufacturing process changes needed for new programs and whether any Cohort 2 biopsy data for MTM would be presented at the upcoming ASGCT meeting.

    Answer

    President and CEO Matthew Patterson emphasized that their manufacturing process is a platform technology, completely applicable to new programs like Pompe and AT720 with no fundamental changes needed. He confirmed that the ASGCT presentation will include biopsy data, including 48-week data from Cohort 1 and likely 24-week data from at least the first patient in Cohort 2.

    Ask Fintool Equity Research AI